Αρχική World News Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly Patients...

Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly Patients With STS

Treatment of elderly patients with soft tissue sarcoma (STS) is challenging with a need to take into account comorbidities and vulnerability to medical treatments. Doxorubicin is a standard of care in patients with advanced, inoperable STS. In the EPAZ study, the German researchers tested whether pazopanib has comparable efficacy in first-line treatment of elderly patients with STS and offers better tolerability to doxorubicin. Viktor Grünwald of the Medical School Hannover and University Hospital Essen and colleagues reported on 24 August 2020 in the Journal of Clinical Oncology that pazopanib demonstrated non-inferior efficacy to doxorubicin in first-line treatment of fit elderly patients with STS with improvement in treatment-related myelotoxicity. It also had advantage in adverse events (AEs) profile, such as alopecia, stomatitis, and mucosal inflammation.

Approximately 40% of patients with STS are age 65 years or older. A retrospective analysis in elderly patients indicated that age 80 years or older, ECOG performance status of 2 or higher, and a large number of metastatic sites were associated with poor median overall survival (OS) and indicated that younger and fitter patients were more likely to receive systemic therapy in clinical practice. Furthermore, only low percentage of patients age 65 years or older are included in clinical trials.

Treatment with doxorubicin, drug predominantly used in systemic therapy for advanced or metastatic STS is associated with AEs such as neutropenia and febrile neutropenia. Given the vulnerability of geriatric patients, chemotherapy endangers this patient population and, as a consequence, hospitalisation is frequently required. Pazopanib is a tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptor. It is associated with limited haematologic toxicity and has a global health status comparable to that of placebo. It is the standard of care in advanced and metastatic STS after failure of treatment with anthracyclines.

The study team assumed that the lack of severe haematologic toxicity renders pazopanib a suitable candidate for first-line treatment in elderly patients with STS, thus minimising the risk of febrile neutropenia. They designed the EPAZ trial to test whether pazopanib is not inferior to doxorubicin in patients with STS who are age 60 years or older, while offering a better risk-benefit ratio for neutropenia and febrile neutropenia. Treatment naïve patients with ECOG performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m2 once every 3 weeks for 6 cycles after being randomly assigned in a 2:1 ratio.

Non-inferiority was assumed for progression-free survival (PFS), if the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) was less than 1.8. Neutropenia and febrile neutropenia were key secondary endpoints. The European Organisation for Research and Treatment of Cancer (30-item) Quality of Life Questionnaire and geriatric assessment were used to measure patient reported outcomes.

Pazopanib and doxorubicin were given to 81 and 39 patients, respectively. The median age was 71 years (range, 60-88 years). The PFS was not inferior (HR, 1.00; 95% CI, 0.65 to 1.53). The incidence of grade 4 neutropenia and febrile neutropenia favoured pazopanib. Objective response rates for pazopanib and doxorubicin were 12.3% and 15.4%, respectively. The OS did not differ significantly between arms.

Geriatric assessment revealed 2 or more comorbidities in 15.8% of the patients and impairment of activities of daily living in 28.3% of patients.

The authors concluded that pazopanib is not inferior in terms of efficacy compared with doxorubicin, rendering pazopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older. There was superiority with pazopanib in terms of neutropenia and febrile neutropenia in elderly patients with STS. Overall incidence of toxicity remained similar for both treatments, but there were differences in the AE profiles that may help tailoring treatment to individual needs in this population.

The authors underlined that the currently predominantly fit elderly patients are selected to participate in the clinical trials. Future studies should focus on frail patients determined by geriatric assessment to develop a therapeutic strategy for this vulnerable patient population. 

Reference

Grünwald V, Karch A, Schuler M, et al. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. JCO; Published online 24 August 2020. DOI: http://ascopubs.org/doi/full/10.1200/JCO.20.00714

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...